The company's medical platform uses antibody technologies to analyze the human plasma proteome, which contains biomarkers for health and disease. Alamar Biosciences aims to create the world's most sensitive proteomics platform to empower new biomarker discoveries for early detection and prevention of common diseases, transforming the field of proteomics for precision health.